BASKING RIDGE, N.J., April 10, 2006 (PRIMEZONE) -- VioQuest Pharmaceuticals, Inc. (OTCBB:VQPH), a New Jersey-based biopharmaceutical company focused on acquiring, developing and commercializing targeted cancer compounds, will present at the BIO 2006 Annual International Convention on Wednesday, April 12th, at 9:15 AM (CT) in Room A of McCormick Place South, Level 3, Exhibit Hall A. The event, which is expected to feature more than 1,600 exhibitions and over 18,000 expected attendees, will be held at The McCormick Place Convention Center in downtown Chicago from April 9 through 12, 2006.
During the presentation, Daniel Greenleaf, president and CEO of VioQuest, will provide a comprehensive company overview, including an update on recent corporate and scientific developments.
Additional information regarding the conference can be found at www.bio.org/events/2006/.
About VioQuest Pharmaceuticals, Inc.
VioQuest Pharmaceuticals, Inc. acquires, develops, and commercializes targeted late preclinical and early clinical stage therapies with unique mechanisms of action for oncology, viral and autoimmune disorders. A leader in personalized therapeutics, VioQuest has two targeted therapeutics in clinical trials: VQD-001, an inhibitor of specific protein tyrosine phosphatases, has shown compelling preclinical activity in both renal and melanoma cancers, and VQD-002 which has been shown to inhibit the phosphorylation of Akt which can be seen in abnormal levels in some breast, ovarian, colorectal, pancreatic cancers, and leukemia.
VioQuest's subsidiary Chiral Quest, a pioneer in asymmetric chemocatalysis and custom synthesis, offers its proprietary technology products to well-known pharmaceutical and fine chemical companies worldwide to improve their production efficiencies and, in some instances, to increase the overall safety and efficacy of the underlying drug.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of VioQuest's research programs and compounds will be successfully commercialized. Risks, uncertainties and assumptions also include the possibility that the market for the sale of certain products may not develop as expected; and that development of these products may not proceed as planned. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2005. VioQuest assumes no obligation and does not intend to update these forward-looking statements, except as required by law.